MS Views & News Awards Questcor With “Recognition of Appreciation” Award Multiple Sclerosis Advocacy

Questcor Pharmaceuticals, Inc. is a drug development company with a viable Multiple Sclerosis drug called H.P. Acthar® Gel, which is currently approved in the U.S. by the FDA for the treatment of acute exacerbations of multiple sclerosis in adults. However, in addition to developing and commercializing MS therapies, the company has also gone above and beyond in helping to support the multiple sclerosis patient population — and is now being honored for it.

Yesterday, the company announced that MS Views & News, Inc., a popular MS advocacy group, had awarded them with a “Recognition of Appreciation” Award for their steady commitment to serving those with the disease.

Stuart Schlossman, President and founder of MS Views & News, was thankful for Questcor’s efforts, and attributed the award to the company’s unique, steadfast approach to connecting closely with those with Multiple Sclerosis: “We are very proud to recognize Questcor for its exemplary support in helping to provide services to the multiple sclerosis community,” he said. “Because of Questcor’s steadfast dedication to the not-for-profit community, MS Views and News is readily able to reach out to tens of thousands of people affected by multiple sclerosis, including their caregivers and healthcare providers.”

The award was officially presented yesterday by Mr. Schlossman to Questcor vice presidents Fran Olson and Darlene Romine at an awards ceremony and reception in Dallas, which was held in conjunction with the Consortium of Multiple Sclerosis Centers Meeting & Exhibition.

[adrotate group=”4″]

Steve Cartt, Questcor’s Chief Operating Officer, underscored his company’s commitment to continuing to improve the quality of life of MS patients through their own efforts and outreach: “Questcor is honored to receive this recognition from MS Views & News. We are committed to serving the needs of MS patients, their families and the healthcare providers who care for them. Our work together has helped bridge an information and awareness gap related to the care of patients suffering from MS relapses, an area of medicine that historically has received little attention. We look forward to continuing this important partnership in the future and furthering these important educational efforts for MS patients.”